Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.54 |
| ▸ | HRH2 | P25021 | 8/20 | 0.54 |
| ▸ | HRH1 | P35367 | 8/20 | 0.54 |
| ▸ | MEN1 | O00255 | 11/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713974 | 0.90 | HRH3 (0.46) | HRH3HRH2HRH1MEN1KMT2A | |
| SCHEMBL1715453 | 0.88 | HRH3 (0.50) | HRH3HRH2HRH1MEN1KMT2A | |
| SCHEMBL1715204 | 0.86 | MMP2 (0.41) | HRH3HRH2HRH1 | |
| SCHEMBL1714536 | 0.79 | HRH2 (0.60) | HRH3HRH2HRH1MEN1 | |
| SCHEMBL7245807 | 0.77 | HRH2 (0.71) | HRH3HRH2HRH1 | |
| SCHEMBL5622767 | 0.76 | HRH3 (0.50) | HRH3HRH2HRH1MEN1KMT2A | |
| SCHEMBL1714253 | 0.75 | HRH2 (0.68) | HRH3HRH2HRH1 | |
| SCHEMBL12461933 | 0.75 | HRH3 (0.54) | HRH3HRH2HRH1MEN1KMT2A | |
| SCHEMBL1714805 | 0.75 | HRH2 (0.68) | HRH3HRH2HRH1 | |
| SCHEMBL1619383 | 0.75 | KCNH2 (0.51) | HRH3HRH2HRH1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | HRH3 395/4885HRH2 284/4885HRH1 386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.